In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Knight Cancer Institute, Doernbecher's Childrens Hospital, Oregon Health & Science University, Portland, Oregon, USA.
Jason M
JM
Glover
Marc
M
Loriaux
Jeffrey W
JW
Tyner
Brian J
BJ
Druker
Bill H
BH
Chang
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002886:Chromosomes, Human, Pair 17; D002888:Chromosomes, Human, Pair 19; D000069439:Dasatinib; D006801:Humans; D066298:In Vitro Techniques; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib